JP6061935B2 - 心的外傷後ストレス障害（ｐｔｓｄ）のための診断用バイオマーカーを検出及び監視するため、並びに同障害の自殺型と非自殺型とを識別するためのプロセス及びキット - Google Patents

心的外傷後ストレス障害（ｐｔｓｄ）のための診断用バイオマーカーを検出及び監視するため、並びに同障害の自殺型と非自殺型とを識別するためのプロセス及びキット Download PDF

Info

Publication number
JP6061935B2
JP6061935B2 JP2014530910A JP2014530910A JP6061935B2 JP 6061935 B2 JP6061935 B2 JP 6061935B2 JP 2014530910 A JP2014530910 A JP 2014530910A JP 2014530910 A JP2014530910 A JP 2014530910A JP 6061935 B2 JP6061935 B2 JP 6061935B2
Authority
JP
Japan
Prior art keywords
ptsd
amount
protein
suicide
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014530910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014531585A (ja
JP2014531585A5 (enExample
Inventor
ポラード，ハーヴェイ
シャン，レイ
エイデルマン，オフェル
ウルサノ，ロバート，ジェイ．
リ，ヘ
スー，トン−ピン
ワン，ケヴィン，カ−ワン
ヘイズ，ロナルド，エル．
Original Assignee
ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン，インコーポレーテッド
ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン，インコーポレーテッド
バンヤン・バイオマーカーズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン，インコーポレーテッド, ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン，インコーポレーテッド, バンヤン・バイオマーカーズ・インコーポレイテッド filed Critical ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン，インコーポレーテッド
Publication of JP2014531585A publication Critical patent/JP2014531585A/ja
Publication of JP2014531585A5 publication Critical patent/JP2014531585A5/ja
Application granted granted Critical
Publication of JP6061935B2 publication Critical patent/JP6061935B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • G01N33/5438—Electrodes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2014530910A 2011-09-14 2012-09-14 心的外傷後ストレス障害（ｐｔｓｄ）のための診断用バイオマーカーを検出及び監視するため、並びに同障害の自殺型と非自殺型とを識別するためのプロセス及びキット Expired - Fee Related JP6061935B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161534560P 2011-09-14 2011-09-14
US61/534,560 2011-09-14
US201161569047P 2011-12-09 2011-12-09
US61/569,047 2011-12-09
PCT/US2012/055639 WO2013040502A2 (en) 2011-09-14 2012-09-14 Processes and kits to detect and monitor for diagnostic biomarkers for post traumatic stress disorder (ptsd) and to differentiate between suicidal and non-suicidal form of the disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016241059A Division JP6371367B2 (ja) 2011-09-14 2016-12-13 心的外傷後ストレス障害（ｐｔｓｄ）のための診断用バイオマーカーを検出及び監視するため、並びに同障害の自殺型と非自殺型とを識別するためのプロセス及びキット

Publications (3)

Publication Number Publication Date
JP2014531585A JP2014531585A (ja) 2014-11-27
JP2014531585A5 JP2014531585A5 (enExample) 2016-08-18
JP6061935B2 true JP6061935B2 (ja) 2017-01-18

Family

ID=47884009

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014530910A Expired - Fee Related JP6061935B2 (ja) 2011-09-14 2012-09-14 心的外傷後ストレス障害（ｐｔｓｄ）のための診断用バイオマーカーを検出及び監視するため、並びに同障害の自殺型と非自殺型とを識別するためのプロセス及びキット
JP2016241059A Expired - Fee Related JP6371367B2 (ja) 2011-09-14 2016-12-13 心的外傷後ストレス障害（ｐｔｓｄ）のための診断用バイオマーカーを検出及び監視するため、並びに同障害の自殺型と非自殺型とを識別するためのプロセス及びキット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016241059A Expired - Fee Related JP6371367B2 (ja) 2011-09-14 2016-12-13 心的外傷後ストレス障害（ｐｔｓｄ）のための診断用バイオマーカーを検出及び監視するため、並びに同障害の自殺型と非自殺型とを識別するためのプロセス及びキット

Country Status (7)

Country Link
US (2) US20150259740A1 (enExample)
EP (1) EP2756313A4 (enExample)
JP (2) JP6061935B2 (enExample)
CN (2) CN103959067B (enExample)
AU (2) AU2012308305B2 (enExample)
CA (1) CA2846625A1 (enExample)
WO (1) WO2013040502A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12120394B2 (en) 2007-11-21 2024-10-15 Rovi Guides, Inc. Maintaining a user profile based on dynamic data

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
WO2010019553A2 (en) 2008-08-11 2010-02-18 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
US20140018299A1 (en) * 2012-07-10 2014-01-16 Banyan Biomarkers, Inc. Method and device to detect, monitor and promote neural regeneration and improvement of cognitive function in a subject suffering from neural injury
WO2015066211A1 (en) * 2013-10-29 2015-05-07 Banyan Biomarkers, Inc. Uch-l1 isoforms, assays and devices for detection of a neurological condition
WO2017062568A1 (en) * 2015-10-08 2017-04-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Biomarkers for diagnosing post traumatic stress disorder
US11078298B2 (en) 2016-10-28 2021-08-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
EP3327134A1 (en) * 2016-11-28 2018-05-30 Carsten Korth Method and biomarkers for in vitro diagnosis of mental disorders
EP3480597A1 (en) * 2017-11-06 2019-05-08 Stalicla S.A. Biomarker assay for use in monitoring autism
JP7231160B2 (ja) * 2018-04-19 2023-03-01 国立大学法人 東京大学 対象における疾患の診断を補助するための方法及びキット
WO2020159965A1 (en) * 2019-01-30 2020-08-06 University Of South Florida Method for detection and analysis of cerebrospinal fluid associated ube3a
CN115993387A (zh) * 2021-10-20 2023-04-21 南开大学 一种抑郁症标志物的评估方法及其应用
CN117451995A (zh) * 2021-12-06 2024-01-26 上海市精神卫生中心（上海市心理咨询培训中心） 用于预测应激后精神心理症状发生的免疫检测试剂盒及应用
WO2024138187A1 (en) * 2022-12-22 2024-06-27 Trugenomix Health Inc. Genetic biomarkers for identification of ptsd and major depression
WO2025166069A1 (en) * 2024-01-30 2025-08-07 Trugenomix Health Inc. A novel biomarker for the identification of ptsd

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004135667A (ja) * 2002-09-27 2004-05-13 Japan Science & Technology Agency 血液を用いた統合失調症の診断方法
EP1597392A1 (en) * 2003-02-21 2005-11-23 Novartis AG Methods for the prediction of suicidality during treatment
EP1745149A4 (en) * 2004-04-15 2008-08-06 Univ Florida NEURALE PROTEINS AS BIOMARKERS FOR INJURY TO THE NERVOUS SYSTEM AND OTHER NEURAL DISORDERS
WO2006013561A2 (en) * 2004-08-02 2006-02-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for diagnosing and treating post traumatic stress disorder
CN101410518A (zh) * 2006-03-24 2009-04-15 诺瓦提斯公司 治疗HPV感染的dsRNA组合物和方法
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
DE102007022669A1 (de) * 2007-05-11 2008-11-20 Carsten Dr. Korth Verwendung von CRMP1 als Marker für chronisch psychiatrische Erkrankungen
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
WO2009059192A1 (en) * 2007-11-02 2009-05-07 Cornell University Materials and methods for gene mediated therapy of psychiatric disorders
JP2011511301A (ja) * 2008-02-04 2011-04-07 バンヤン・バイオマーカーズ・インコーポレイテッド 脳損傷を診断または治療するための方法
EP2329260A4 (en) * 2008-03-04 2011-08-03 Ridge Diagnostics Inc DIAGNOSIS AND MONITORING OF DEPRESSIVE DISORDERS BASED ON A PLURALITY OF BIOMARKER PANELS
EP2108657A1 (en) * 2008-04-08 2009-10-14 DKFZ Deutsches Krebsforschungszentrum Peptides for inhibiting the HPV-E6 oncoprotein
EP3586923B1 (en) * 2008-07-14 2021-06-16 Arizona Board Of Regents For And On Behalf Of Arizona State University Devices for modulating cellular activity using ultrasound
EP2963129A3 (en) * 2008-11-12 2016-05-11 University of Utah Research Foundation Autism associated genetic markers
WO2010093872A2 (en) * 2009-02-13 2010-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular-based method of cancer diagnosis and prognosis
US20120269765A1 (en) * 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
WO2011031786A2 (en) * 2009-09-08 2011-03-17 Laboratory Corporation Of America Holdings Compositions and methods for diagnosing autism spectrum disorders
WO2011123844A2 (en) * 2010-04-01 2011-10-06 Banyan Biomarkers, Inc. Markers and assays for detection of neurotoxicity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12120394B2 (en) 2007-11-21 2024-10-15 Rovi Guides, Inc. Maintaining a user profile based on dynamic data

Also Published As

Publication number Publication date
JP2014531585A (ja) 2014-11-27
EP2756313A4 (en) 2015-04-22
AU2018201249A1 (en) 2018-03-15
EP2756313A2 (en) 2014-07-23
US20170242036A1 (en) 2017-08-24
CN108593926A (zh) 2018-09-28
AU2012308305B2 (en) 2017-11-23
JP6371367B2 (ja) 2018-08-08
US20150259740A1 (en) 2015-09-17
CA2846625A1 (en) 2013-03-21
JP2017078720A (ja) 2017-04-27
AU2012308305A1 (en) 2014-03-20
CN103959067B (zh) 2018-04-24
WO2013040502A3 (en) 2013-05-10
CN103959067A (zh) 2014-07-30
WO2013040502A2 (en) 2013-03-21
AU2018201249B2 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
JP6371367B2 (ja) 心的外傷後ストレス障害（ｐｔｓｄ）のための診断用バイオマーカーを検出及び監視するため、並びに同障害の自殺型と非自殺型とを識別するためのプロセス及びキット
EP2965090B1 (en) Methods and compositions for the diagnosis of alzheimer's disease
JP2022501016A (ja) 脳障害、特に、認知障害の診断および治療のための長鎖ノンコーディングＲＮＡ（ｌｎｃＲＮＡ）
CN107636468A (zh) 用于预测认知退化的风险的方法
EP3134552B1 (en) Methods, processes, devices and kits for the measurement of post traumatic stress disorder microrna markers
WO2021228125A1 (en) Protein markers for assessing alzheimer's disease
US20220057409A1 (en) Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair
CN109996895A (zh) 体外诊断精神障碍的方法和生物标志物
KR102047479B1 (ko) 노년기우울증 검출방법 및 진단키트
Paap et al. Molecular biomarkers in multiple sclerosis
US20230333121A1 (en) Methods and compositions relating to biomarkers for neurodegenerative diseases
WO2013009183A1 (en) Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness
WO2023196927A1 (en) Methods and kits for assessing alzheimer's disease
WO2011041725A2 (en) Schizophrenia treatment response biomarkers
WO2011109503A1 (en) Novel csf biomarkers for alzheimer's disease and frontotemporal lobar degeneration
You et al. Lack of association between BDNF Val66Met gene polymorphism and late-onset depression in a Chinese Han population
HK40083580A (en) Protein markers for assessing alzheimer's disease
WO2024042208A1 (en) Method for the detection of dementia
Kouli The neuroinflammatory basis of disease progression and cognitive impairment in Parkinson's disease

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150507

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160622

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161213

R150 Certificate of patent or registration of utility model

Ref document number: 6061935

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees